Go to Member Homepage
Go to Submission Portal
Forgot your USERNAME OR PASSWORD?
CVP LinkedIn Group
Find us on the popular social networks
The Division for Cardiovascular Pharmacology (CVP) serves members with interests in all aspects of cardiovascular pharmacology research from the molecular level to whole animal and clinical studies. Specific areas include, but are not limited to, mechanisms of cardiovascular drug action, autonomic pharmacology, cell signaling, cardiac pharmacology, endothelial and smooth muscle cell pharmacology, hemostasis and thrombosis, blood vessel wall interactions, and mechanisms involved in the pathogenesis, diagnosis and treatment of cardiac, renal, pulmonary and cerebral vascular disease, including hypertension, coronary artery disease and stroke.
Save the date November 2016 to join fellow vascular biologist for what plans to be an exciting symposium. This symposium, “Mechanisms of Vasodilatation”, will celebrate the 30th anniversary of the discovery of nitric oxide (NO) as an intercellular messenger.
Dr. Pancras Wong along with five of his colleagues at Bristol-Myers Squibb received the prestigious American Chemical Society (ACS) 2015 Heroes of Chemistry Award for the discovery of Eliquis (apixiban).
Main Line Health has named Charles Antzelevitch, PhD, FACC, FAHA, FHRS, executive director of the cardiovascular research program at Lankenau Institute for Medical Research and director of research at Lankenau Heart Institute.
Dr. Bradley McConnell of the University of Houston, Texas Medical Center, received a National Institutes of Health/NHLBI R15 Academic Research Career Enhancement Award.
The Division for Cardiovascular Pharmacology congratulates its winners for their outstanding posters and oral sessions at EB 2015.
©The American Society for Pharmacology and Experimental Therapeutics (ASPET)9650 Rockville Pike, Bethesda, Maryland 20814-3995
ASPET.org is best viewed with Internet Explorer 7+, Firefox 3.5+ and Safari 3+.